Publication | Closed Access

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Neurodegenerative DiseasesAscending-dose StudyAlzheimer's Disease11C-pib Pet AssessmentBiomarkersVascular DementiaNeurochemical BiomarkersNeurologyNeuroscienceMedicineNeurological AssessmentFibrillar Amyloid-β LoadTreatment